Jan‐Erik Westlin

1.5k total citations
36 papers, 1.1k citations indexed

About

Jan‐Erik Westlin is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Neurology. According to data from OpenAlex, Jan‐Erik Westlin has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Radiology, Nuclear Medicine and Imaging and 12 papers in Neurology. Recurrent topics in Jan‐Erik Westlin's work include Neuroendocrine Tumor Research Advances (12 papers), Neuroblastoma Research and Treatments (12 papers) and Radiopharmaceutical Chemistry and Applications (9 papers). Jan‐Erik Westlin is often cited by papers focused on Neuroendocrine Tumor Research Advances (12 papers), Neuroblastoma Research and Treatments (12 papers) and Radiopharmaceutical Chemistry and Applications (9 papers). Jan‐Erik Westlin collaborates with scholars based in Sweden, United States and Norway. Jan‐Erik Westlin's co-authors include Sten Nilsson, Kjell Öberg, Eva Tiensuu Janson, K. W. Borch, Lise Balteskard, Øyvind S. Bruland, Roy H. Larsen, Sophie D. Fosså, Håkan Åhlström and Sven Påhlman and has published in prestigious journals such as Cancer, Clinical Cancer Research and Pain.

In The Last Decade

Jan‐Erik Westlin

35 papers receiving 1.1k citations

Peers

Countries citing papers authored by Jan‐Erik Westlin

Since Specialization

Citations

This map shows the geographic impact of Jan‐Erik Westlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan‐Erik Westlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan‐Erik Westlin more than expected).

Fields of papers citing papers by Jan‐Erik Westlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan‐Erik Westlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan‐Erik Westlin. The network helps show where Jan‐Erik Westlin may publish in the future.

Co-authorship network of co-authors of Jan‐Erik Westlin

This figure shows the co-authorship network connecting the top 25 collaborators of Jan‐Erik Westlin. A scholar is included among the top collaborators of Jan‐Erik Westlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan‐Erik Westlin. Jan‐Erik Westlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA) 2008 ·Radiotherapy and Oncology ·Roger Henriksson, Jacek Capala, Annika Michanek, (unknown), Leif G. Salford, Lars Franzén, Erik Blomquist, Jan‐Erik Westlin, A. Tommy Bergenheim	123
2	Boron neutron capture therapy (BNCT) for glioblastoma 4 multiforme: A phase II study evaluating a prolonged high-dose of 5 boronophenylalanine (BPA) at the Studsvik facility in Sweden 2008 ·Radiotherapy and Oncology ·Roger Henriksson, Jacek Capala, Annika Michanek, (unknown), Leif G. Salford, Lars Franzén, Erik Blomquist, Jan‐Erik Westlin, Tommy Bergenheim	2
3	Octreoscan in patients with bronchial carcinoid tumours 2003 ·Clinical Endocrinology ·Donald Granberg, Anders Sundin, Eva Tiensuu Janson, Kjell Öberg, Britt Skogseid, Jan‐Erik Westlin	86
4	Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with 131I labeled ligands or antibodies 2000 ·International Journal of Radiation OncologyBiologyPhysics ·Torbjörn Hartman, Hans Lundqvist, Jan‐Erik Westlin, Jörgen Carlsson	31
5	Expression of epidermal growth factor receptor in urinary bladder cancer metastases 1998 ·International Journal of Cancer ·(unknown), Kenneth Wester, Anna Sjöström, Anders Holmberg, Sten Nilsson, Jörgen Carlsson, Jan‐Erik Westlin, Christer Busch, Per‐Uno Malmström	1
6	Expression of epidermal growth factor receptor in urinary bladder cancer metastases 1998 ·International Journal of Cancer ·(unknown), Kenneth Wester, (unknown), Anders Holmberg, Sten Nilsson, Jörgen Carlsson, Jan‐Erik Westlin, Christer Busch, Per‐Uno Malmström	41
7	Synthesis, In Vivo Rhesus Monkey Biodistribution and In Vitro Evaluation of a 11C-Labelled Potent Aromatase Inhibitor: [N-methyl-11C]Vorozole 1998 ·Nuclear Medicine and Biology ·Pelle Lidström, Thomas A. Bonasera, (unknown), Bo Lindblom, Frank Leigh Lu, (unknown), Mats Bergström, Jan‐Erik Westlin, Bengt Långström	26
8	Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma 1997 ·Nuclear Medicine and Biology ·Karl‐Mikael Kälkner, Claes Ginman, Sten Nilsson, Mats Bergström, Gunnar Antoni, Håkan Åhlström, Bengt Långström, Jan‐Erik Westlin	17
9	The Angiogenesis Inhibitor TNP-470 Reduces the Growth Rate of Human Neuroblastoma in Nude Rats 1997 ·Pediatric Research ·Erik Wassberg, Sven Påhlman, Jan‐Erik Westlin, Rolf Christofferson	72
10	Objective responses after fractionated infusional brachytherapy of unresectable pancreatic adenocarcinomas 1997 ·Cancer ·Jan‐Erik Westlin, (unknown), Ulrike Garske, Thomas Linné, Magne Aas, Bengt Glimelius, (unknown), Stanley E. Order, Sten Nilsson	1
11	Estramustine-Binding Protein (EMBP) in Renal Cell Carcinoma Immunohistochemistry, Immunoscintigraphy and in Vitro Estramustine Effects 1996 ·Acta Oncologica ·M Edgren, Jan‐Erik Westlin, Henry Letocha, Hans Nordgren, Karl‐Mikael Kälkner, Sten Nilsson	3
12	^99MTc-Dextran-Antibody Conjugates : Labelling procedures 1996 ·Acta Oncologica ·Marcela Márquez, Jan‐Erik Westlin, Sten Nilsson, Anders Holmberg	2
13	A search for the optimal positron emitting label for DTPA-octreotide 1995 ·Journal of Labelled Compounds and Radiopharmaceuticals ·Alexander Bruskin, Hans Lundqvist, Jan‐Erik Westlin, (unknown), Vladimir Tolmachev	1
14	Rapid, reproducible pain relief with [131I]iodine-meta-iodobenzylguanidine in a boy with disseminated neuroblastoma 1995 ·Pain ·Jan‐Erik Westlin, Henry Letocha, Åke Jakobson, Peter Strang, Ulla Martinsson, Sten Nilsson	6
15	Estramustine potentiates the radiation effect in human prostate tumor transplant in nude mice 1994 ·The Prostate ·(unknown), Jan‐Erik Westlin, G. Rikner, Sten Nilsson	10
16	Immunotargeting with Monoclonal Cytokeratin 8 Antibodies of Human Urothelial Cancer Transplanted to Nude Mice 1993 ·Acta Oncologica ·Henry Letocha, Sten Nilsson, (unknown), Jonas Ekblom, Henrik Arnberg, (unknown), Jan‐Erik Westlin	5
17	Three-Dimensional OctreoScan111 Spect of Abdominal Manifestation of Neuroendocrine Tumours 1993 ·Acta Oncologica ·Jan‐Erik Westlin, Håkan Åhlström, (unknown), Kjell Öberg, Sten Nilsson	8
18	Distribution and Elimination of the Somatostatin Analogue (¹¹¹In-DTPA-D-Phe¹)-Octreotide (OctreoScan111) 1993 ·Acta Oncologica ·Henrik Arnberg, Jan‐Erik Westlin, (unknown), Sten Nilsson	6
19	Characterization and Uptake of Radiolabelled Meta-Iodobenzylguanidine (Mibg) in a Human Neuroblastoma Heterotransplant Model in Athymic Rats 1993 ·Acta Oncologica ·Sten Nilsson, Sven Påhlman, Henrik Arnberg, Henry Letocha, Jan‐Erik Westlin	6
20	Somatostatin Receptor Scintigraphy of Carcinoid Tumours Using the [¹¹¹In-Dtpa-D-Phe¹]-Octreotide 1993 ·Acta Oncologica ·Jan‐Erik Westlin, Eva Tiensuu Janson, Henrik Arnberg, Håkan Åhlström, Kjell Öberg, (unknown)	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact